ATNX

Oraxol with pembrolizumab

Solid Tumors

Phase 1 Expansion Enrollment

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

Catalyst Events

  • TBA

Clinical Trial

  • NCT03588039: Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

Time Line

Related Links

  • February 27, 2020 Enroll patients in dose expansion part of Phase 1 trial of Oral Paclitaxel in combination with pembrolizumab for the treatment of advanced solid tumors (H2-2020).


Prior Data Links

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Will ATNX stock price pop if O...

ATNX's oraxol has shown some pretty good data in metastatic breast cancer. And oral paclitaxel vs. IV paclitaxel seems to have some patient convenience advantage. However, the stock has not responded ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon